RxDoctor Payments Data

Deepak Patel, MD

Sports Medicine · Yorkville, ILNPI 1457346074

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 632 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations.

$10,435in general payments, 2019–2025

Across 632 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • Amgen$1K
  • AbbVie$941
  • Lilly USA, LLC$904
  • GSK$806
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$10,435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,435 in reported general payments places this provider in the 75th percentile of 233 sports medicine providers in Illinois.

See all sports medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$117,777
Medicare patients
190
Services billed
1,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$42,349
JardianceEmpagliflozin14$18,914
JanuviaSitagliptin Phosphate17$13,968
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,892
AmantadineAmantadine Hcl18$599
Albuterol Sulfate HfaAlbuterol Sulfate15$582
Tamsulosin Hcl44$539
Omeprazole36$475
Lisinopril84$469
Simvastatin62$467
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol11$459
Duloxetine Hcl38$453
Metoprolol Succinate22$414
Levothyroxine Sodium56$400
Atorvastatin Calcium46$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,311$42,34926 claims
Boehringer IngelheimJardiance$1,486$18,91414 claims
MerckJanuvia$460$13,96817 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$22$40056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 233 sports medicine providers in Illinois.

Other sports medicine in Yorkville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →